Table 1: Characteristics of patients.
|
Variable |
n |
% |
|
Sex |
|
|
|
Male |
26 |
45 |
|
Female |
32 |
55 |
|
Age at diagnosis (year) |
|
|
|
Mean ± SD |
5.5 ± 3.8 |
|
|
Median (IQR25-75) |
4.2 (4.3) |
|
|
ALL risk group |
|
|
|
SRG |
17 |
30 |
|
IRG |
36 |
61 |
|
HRG |
5 |
9 |
|
Immunophenotypes |
|
|
|
Pre-B |
50 |
86 |
|
Pro-B |
8 |
14 |
|
T-cell |
- |
- |
|
Vitamin D supplementation while under chemotherapy |
|
|
|
Received |
23 |
40 |
|
Not received |
25 |
60 |
|
Bone mineral density (g/cm2) |
|
|
|
Mean ± SD |
0.52 ± 0.13 |
|
|
Median (IQR25-75) |
0.48 (0.11) |
|
|
Z-score |
|
|
|
Mean ± SD |
-1.82 ± 3.75 |
|
|
Median (IQR25-75) |
-1.5 (-1.4) |
|
|
BMD according to z-score |
|
|
|
Normal |
21 |
38 |
|
Low bone density |
29 |
50 |
|
Osteoporosis |
8 |
12 |
SD: Standard deviasion; IQR: Interquartile range; ALL: Acute lymphoblastic leukemia; SRG: Standard risk group; IRG: Intermediate risk group; HRG: High risk group; BMD: Bone mineral density